There have been at least a dozen very encouraging cancer treatments in the last seventy years.  The Rife frequency machine, Laetrile, Hoxsey, Antineoplastons, Coley’s Toxins, Glyoxylide, Hydrazine Sulfate, Krebiozen, Immuno-Augmentative Therapy, Dr. Max Gerson’s Diet, to name a few. They all have two things in common. The people advocating the therapy are branded charlatans or quacks and the treatment is denounced as worthless by scientists who have been selling us out for generations.

See my nonprofit web site for more information

The author of the article below, Ralph Moss, has been documenting this for over 20 years. His life was changed in the late 1970's when he exposed the cover-up by Memorial Sloan-Kettering Cancer Center in New
York. They suppressed the benefits of Laetrile/amygdalin in fighting cancer. Why would they do this you may ask? If an effective cancer treatment was found in nature, it would spell economic disaster for the cancer indu$try.

Also see my Why would doctors suppress an effective cancer treatment section

Thank you. Gavin Phillips

Exposing the Cancer Racket

30th Anniversary of the War on Cancer

By Ralph Moss (Ph.D)

December 31, 2001 marked the 30th anniversary of the "War on
Cancer." In 1971, President Nixon signed the National Cancer Act,
launching a multi-billion dollar assault on the dread disease.
Congress designated this Act "a national crusade to be accomplished
by 1976 in commemoration of the 200th anniversary of our country."
Well, the Bicentennial came and went and cancer is still with us. In
1962, there were 278,000 deaths from cancer in the US. By 1982, that
was 433,000. This year it reached 553,400. There is no victory in
sight.

Why so little progress? Health authorities neglect everything but the

toxic drug approach. Prevention is discredited, and alternative
medicine has largely been placated. The media, so aggressive in other

matters, is a pussycat when it comes to investigating cancer. Nearly
everyone dances to the tune of "Big Pharma."

Magazine Covers (above)
Each year, there is an orgy of false expectations about cures. In
May, the FDA approved a drug called Gleevec (STI-571) as a treatment
for chronic myelogenous leukemia (CML). The media went wild. Barron's

headlined: "Investing in Health, Curing Cancer!" It claimed "we are
finally winning the war." The New York Times announced "the long-
awaited payoff from decades of research into the molecular biology of

cancer." Time went over the top. Its May 28, 2001 cover demanded,"Is
this the breakthrough we've been waiting for?" The word "CANCER" was
two inches high! It referred to "a magic pill, a miracle
breakthrough." Not surprisingly, Gleevec flew off the shelves, at a
cost per person of $30,000 per year. Although CML affects only 0.3
percent of all cancer patients, every kind of patient wanted
this "miracle." You can hardly blame them. (View photo above, right)

But where's Gleevec now? At a recent symposium in New York
researchers quietly voiced their growing skepticism. "There are
provocative datain CML patients showing these are highly resistant to

Gleevec," said Connie J. Eaves, PhD of British Columbia. "Stem cells
in CML may not be responsive to this agent at all. We are completely
swept away by responses that may not have very much to do with cure
at all."

Rudiger Hehlmann, MD of Heidelberg, Germany, agreed. He told
researchers to remember that there are no survival data for the use
of this drug yet, except for patients in blast crisis. "Euphoria is a

bad advisor in treatment," he added, sardonically.

John Goldman, MD, chief of hematology at Hammersmith Hospital,
London, said Gleevec as a single agent will not even cure the
majority of CML patients. "We do not know what the basis for
resistance is. It may be acquired, or the disease may already be
resistant before the drug is used."

"When Gleevec first came on the scene," added Richard T. Silver, MD
of Presbyterian Hospital, NYC, it seemed that the question of
treating CML was almost all solved. "But in the last year we have all

begun to appreciate how much we have to learn about how to use this
agent."

At the same time, critics were warned that they'd better get on the
Gleevec bandwagon. "Those who don't get on it are going to be run
over by it," said one speaker. (All these quotes come from a trade
magazine, Oncology Times, and were not intended for public
consumption.)

By next year, Gleevec may have gone the way of interferon,
interleukin, Endostatin, and a host of other seven day wonders. The
leaders of the cancer war may be on to some other miracle drug. At
some point, the public will have to stand up and say, "Enough!" Now
might be a good time, since the NCI has a new director. It is time
for the "war on cancer" to focus on prevention and the best
complementary and alternative treatments. Such approaches may not
make a pile of money for the big drug companies, but they hold a
great deal more promise for cancer patients.